Long-term Follow-up After Prostate-Specific Antigen Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
Journal of Urologic Oncology · 31.07.2026 · 24 (2) · 137-141
DOI: 10.22465/juo.265200100005n ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Urologic Oncology, erschienen am 31.07.2026. Verfasst von Eric A. Miller und 1 weiteren Autor:innen. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Current prostate cancer (PCa) screening guidelines for prostate-specific antigen (PSA) testing recommend informed discussions between patient and provider for men aged 55–69 years due to inconsistent trial results and benefit to harm ratio considerations. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial has followed participants for almost 30 years to assess the long-term impacts of screening, which can alter the balance of benefits and harms. For PCa screening, 76,678 men were randomized to a screening or usual care arm of the trial. PCa incidence and mortality were ascertained through active followup through 2009 and through linkages with cancer registries and the National Death Index, respectively, until 2021 and 2022. We compared incidence and mortality rates between screening arms and rates by stage and tumor grade for incidence. There was no significant difference in overall mortality rates (relative risk [RR], 0.93; 95% confidence interval [CI], 0.83–1.05) and incidence was borderline significantly higher in the screening arm (RR, 1.04; 95% CI, 1.00–1.07). There were significant reductions in the incidence of high grade (RR, 0.89; 95% CI, 0.81–0.98) and metastatic tumors (RR, 0.81; 95% CI, 0.66–0.98). Results from the PLCO have demonstrated long-term impacts of PSA screening but no significant reduction in PCa mortality.
Zitieren
APA
Miller, E. A., & Pinsky, P. F. (2026). Long-term Follow-up After Prostate-Specific Antigen Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Journal of Urologic Oncology, 24(2), 137-141. https://doi.org/10.22465/juo.265200100005n
Vancouver
Miller EA, Pinsky PF. Long-term Follow-up After Prostate-Specific Antigen Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Journal of Urologic Oncology. 2026;24(2):137-141. doi:10.22465/juo.265200100005n
BibTeX
@article{Miller2026,
author = {Miller, Eric A. and Pinsky, Paul F.},
title = {Long-term Follow-up After Prostate-Specific Antigen Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial},
journal = {Journal of Urologic Oncology},
year = {2026},
volume = {24},
number = {2},
pages = {137--141},
doi = {10.22465/juo.265200100005n}
}
EUVIMED